Guselkumab: A Review in Moderate to Severe Plaque Psoriasis
Volume: 19, Issue: 6, Pages: 907 - 918
Published: Nov 22, 2018
Abstract
Guselkumab (Tremfya®) is a human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that blocks the interleukin-23 (IL-23)-mediated signalling pathway and is the first in its class to be approved in adults with moderate to severe plaque psoriasis in several countries, including the USA and EU. In the VOYAGE trials, guselkumab was superior to placebo and to adalimumab at week 16 in terms of the proportion of patients achieving an Investigator...
Paper Details
Title
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis
Published Date
Nov 22, 2018
Volume
19
Issue
6
Pages
907 - 918
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History